

## Bölüm 3

# YUMUŞAK DOKU TÜMÖRLERİNDE PATOLOJİK SINIFLANDIRMA

Burçin PEHLİVANOĞLU<sup>1</sup>

### GİRİŞ


Mezenkimal hücrelerden köken alan malign neoplazmlar “sarkom” olarak isimlendirilmektedir. “Sarkom” kelimesi “etsi” anlamına gelen Yunanca “σάρξ (*sarx*)” kelimesinden türemiştir. Sarkomları nonepitelyal nonhematojen dokulardan (kemik, kırkırdak, bağ ve yağ doku) köken alan tümörler olarak tanımlayan Rudolph Virchow’dur (1). Bu bölümde yumuşak doku tümörlerinin patolojik sınıflandırma sistemi ve histopatolojik değerlendirme sırasında dikkat edilmesi gereken özellikler ele alınacak ve sık görülen yumuşak doku tümörlerine değinilecektir.

### YUMUŞAK DOKU TÜMÖRLERİNİN BİYOLOJİK DAVRANIŞLARINA GÖRE SINIFLANDIRILMASI

Dünya Sağlık Örgütü (DSÖ) yumuşak doku tümörlerini biyolojik davranışlarına göre 4 alt gruba ayırmıştır (2): benign, “intermediate”-lokal agresif, “intermediate”-nadir metastaz yapan ve malign.

**Benign** yumuşak doku tümörleri genellikle nüksetmez; nüksetseler bile iyi sınırlı büyüme gösterdiklerinden hemen daima eksizyon ile kür sağlanır. Çok nadiren, benign bir yumuşak doku tümörü uzak metastaz yapabilir (örn. Kütanöz benign fibröz histiyositoma) (2). Guillou ve arkadaşları kütanöz fibröz histiyositom olgularında büyük boyut, artmış sellülarite, anevrizmal değişiklikler, belirgin hücresel pleomorfizm, yüksek mitotik aktivite, tümör nekrozu ve tekrarlayan lokal nükslerin, metastaz gelişimi için risk faktörü olduğunu savunurken (3), Doyle ve Fletcher agresif biyolojik davranışın yalnızca morfolojiye dayanarak öngörüle-meyeceğini öne sürmektedir (4).

<sup>1</sup> Uzm. Dr. Burçin Pehlivanoglu, Adıyaman Üniversitesi Eğitim Araştırma Hastanesi, Tıbbi Patoloji Bölümü, Adıyaman, Türkiye E-posta: burcinp@yahoo.com



**Resim 4.** İndiferansiye pleomorfik hücreli sarkom, hematoksilen-eozin, x400.  
\*(2, 51, 52) no'lu kaynaklardan yararlanılarak hazırlanmıştır. Kısaltmalar: DKA-düz kas aktin; EMA-epitelyal membran antijeni; vWF- von Willebrand faktör; GIST-gastrointestinal stromal tümör; ALT/İDLPS-atipik lipomatöz tümör/iyi diferansiye liposarkom; DDLPS-dediferansiye liposarkom.

## SONUÇ

Histopatolojik değerlendirme ve sınıflandırma yumuşak doku tümörlerinin, özellikle de sarkomların, tedavisinin planlanmasında ve prognoz öngörüsünde büyük öneme sahiptir. Formalinde fikse edilmiş parafin blokta saklanan tümör dokusunda moleküler testlerin uygulanabilirliği bu tümörlerdeki spesifik moleküler değişikliklerin belirlenmesini mümkün kılmakta ve bu hastalara multidisipliner yaklaşımda patolojinin kritik rolünü bir kez daha vurgulamaktadır.

**Anahtar Kelimeler:** Yumuşak doku, sarkom, histopatoloji

## KAYNAKLAR

1. Peltier LF. Historical note on bone and soft tissue sarcoma. J Surg Oncol 1985;30:201-205.
2. Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone. IARC Press, Lyon. . 2013.
3. Guillou L, Gebhard S, Salmeron M, Coindre JM. Metastasizing fibrous histiocytoma of the skin: a clinicopathologic and immunohistochemical analysis of three cases. Mod Pathol 2000;13:654-660.
4. Doyle LA, Fletcher CD. Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. Am J Surg Pathol 2013;37:484-495.
5. Fiore M, MacNeill A, Gronchi A, Colombo C. Desmoid-Type Fibromatosis: Evolving Treatment Standards. Surg Oncol Clin N Am 2016;25:803-826.
6. Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, Salas S, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospec-

- tive cohort from the French Sarcoma Group. *Eur J Cancer* 2017;83:125-131.
7. Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. *Am J Surg Pathol* 2011;35:190-201.
  8. Mangham DC, Kindblom LG. Rarely metastasizing soft tissue tumours. *Histopathology* 2014;64:88-100.
  9. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. *J Clin Oncol* 1996;14:869-877.
  10. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. *J Clin Oncol* 1997;15:350-362.
  11. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. *J Clin Oncol* 1996;14:1679-1689.
  12. Neuville A, Chibon F, Coindre JM. Grading of soft tissue sarcomas: from histological to molecular assessment. *Pathology* 2014;46:113-120.
  13. Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG, Meissner W, et al. A clinical and pathological staging system for soft tissue sarcomas. *Cancer* 1977;40:1562-1570.
  14. Myhre-Jensen O, Kaae S, Madsen EH, Sneppen O. Histopathological grading in soft-tissue tumours. Relation to survival in 261 surgically treated patients. *Acta Pathol Microbiol Immunol Scand A* 1983;91:145-150.
  15. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. *Cancer* 1984;53:530-541.
  16. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. *Int J Cancer* 1984;33:37-42.
  17. van Unnik JA, Coindre JM, Contesso C, Albus-Lutter CE, Schiodt T, Sylvester R, Thomas D, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 1993;29a:2089-2093.
  18. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. *Clin Sarcoma Res* 2016;6:20.
  19. <https://www.cancer.org/cancer/soft-tissue-sarcoma/treating/by-stage.html>. Erişim tarihi: 14.08.2019.
  20. Hoerber I, Spillane AJ, Fisher C, Thomas JM. Accuracy of biopsy techniques for limb and limb girdle soft tissue tumors. *Ann Surg Oncol* 2001;8:80-87.
  21. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, Sastre X, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. *Cancer* 2001;91:1914-1926.
  22. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. *Nat Med* 2010;16:781-787.
  23. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. *Clin Cancer Res* 2012;18:826-838.
  24. Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, Sciot R, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. *J Clin Oncol* 2013;31:608-615.
  25. Bridge JA. The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors. *Mod Pathol* 2014;27 Suppl 1:S80-97.
  26. Henderson-Jackson EB, Bui MM. Molecular Pathology of Soft-Tissue Neoplasms and Its Role in Clinical Practice. *Cancer Control* 2015;22:186-192.

27. Lucas DR, Nascimento AG, Sanjay BK, Rock MG. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. *Am J Clin Pathol* 1994;102:677-683.
28. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. *Am J Surg Pathol* 1997;21:271-281.
29. Dantey K, Schoedel K, Yergiyev O, Bartlett D, Rao UNM. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas. *Hum Pathol* 2017;66:86-92.
30. Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, Ye Y, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. *Lab Invest* 2011;91:1427-1433.
31. Skubitz KM. Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor. *Mayo Clin Proc* 2017;92:947-964.
32. Dervisoglu S, Comunoglu N, Kosemehmetoglu K. Yumuşak doku tümörlerinin histopatolojisi ve sınıflamada yenilikler. *Türk Onkoloji Dergisi* 2015;30:4-14.
33. Jo VY, Doyle LA. Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone. *Surg Oncol Clin N Am* 2016;25:621-643.
34. Fletcher CD. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. *Histopathology* 2014;64:2-11.
35. Gombos Z, Zhang PJ. Glomus tumor. *Arch Pathol Lab Med* 2008;132:1448-1452.
36. Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. *J Dent Res* 2012;91:341-350.
37. Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? *Br J Cancer* 2001;85:831-835.
38. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. *Mod Pathol* 2001;14:595-603.
39. Nascimento AF, Fletcher CD. Spindle cell rhabdomyosarcoma in adults. *Am J Surg Pathol* 2005;29:1106-1113.
40. Walther C, Tayebwa J, Lilljebjorn H, Magnusson L, Nilsson J, von Steyern FV, Ora I, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. *J Pathol* 2014;232:534-540.
41. Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. *Genes Chromosomes Cancer* 2011;50:644-653.
42. Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. *Am J Surg Pathol* 2008;32:924-927.
43. Manner J, Radlwimmer B, Hohenberger P, Mossinger K, Kuffer S, Sauer C, Belharazem D, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. *Am J Pathol* 2010;176:34-39.
44. Miettinen M, Makhlof H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. *Am J Surg Pathol* 2006;30:477-489.
45. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* 2005;29:52-68.
46. Hornick JL, Bundock EA, Fletcher CD. Hybrid schwannoma/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. *Am J Surg Pathol* 2009;33:1554-1561.
47. Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M, Nagel C, et al. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromato-

- sis patients. *Am J Surg Pathol* 2012;36:702-709.
48. Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M. Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis. *Springerplus* 2015;4:375.
  49. Takenaka S, Naka N, Obata H, Joyama S, Hamada K, Imura Y, Kakunaga S, et al. Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. *Jpn J Clin Oncol* 2016;46:522-528.
  50. Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, Sorger J, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer* 2016;63:1771-1779.
  51. Hornick JL. Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors. *Mod Pathol* 2014;27 Suppl 1:S47-63.
  52. Wei S, Henderson-Jackson E, Qian X, Bui MM. Soft Tissue Tumor Immunohistochemistry Update: Illustrative Examples of Diagnostic Pearls to Avoid Pitfalls. *Arch Pathol Lab Med* 2017;141:1072-1091.